On April 23, 2025 Bio-Techne Corporation (NASDAQ: TECH) reported it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL (Press release, Bio-Techne, APR 23, 2025, View Source [SID1234652063]). Bio-Techne’s booths will feature its oncology research portfolio spanning early discovery, translational research, and cell and gene therapy development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR is recognized as one of the world’s most influential cancer research conferences, convening global experts to exchange groundbreaking discoveries and innovations in cancer science and medicine. Bio-Techne will engage with these researchers and industry professionals to highlight its cutting-edge solutions that empower scientific progress across the oncology landscape.

At booth #3049, Bio-Techne will feature its comprehensive portfolio, including high-performance proteins, antibodies, small molecules, cell culture reagents, immunoassays, automated proteomic analysis platforms, and spatial multiomic solutions. These technologies are designed to drive advancements in oncology research, accelerate immune cell therapy development, and support the creation of next-generation diagnostic tools. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will feature its complete solution for accelerating spatial multiomic research, including its protease-free workflows across the RNAscope spatial portfolio. To support the expanded capabilities for multiomic detection on the Leica Bond RX, we will showcase scientific posters and an evening reception on April 27th co-hosted by ACD, Leica Biosystems and Indica Labs.

At booth #3249, Lunaphore, one of Bio-Techne’s spatial biology brands, will present its enhanced end-to-end portfolio that offers high-value spatial biology solutions for the translational research community. Lunaphore’s latest advancements include the launch of the fully-automated, same-section multiomics application for fixed-frozen tissue. Additionally, Lunaphore will bring together the spatial biology community at an exclusive dinner reception on April 28, held in affiliation with AACR (Free AACR Whitepaper), providing a unique opportunity to connect with leaders in the field of multiomics, and explore Lunaphore’s upcoming releases, including innovative tools for HORIZON image analysis software.

"As cancer research advances at an unprecedented pace, Bio-Techne remains committed to providing scientists with the tools they need to drive discovery and innovation," said Kim Kelderman, Bio-Techne’s President and Chief Executive Officer. "Our solutions empower researchers at every stage—from fundamental science to translational applications—helping to shape the future of precision medicine and next-generation cancer therapies. We are excited to connect with the scientific community at AACR (Free AACR Whitepaper) to explore new possibilities in the fight against cancer."

Bio-Techne Presentations and Poster Presentations:

Protein Quantitation for Characterization of Potential Cancer Therapeutics in Early Discovery and Mechanism of Action Insights in Translational Studies
Tuesday, April 29 | 10:00 – 11:00 AM
Exhibit Hall, Spotlight Theater A

Evaluation of IDH1, EGFR, IGF1R, and Ki67 Biomarkers in Glioblastoma Using Lunaphore COMET Platform
Monday, April 28 | 9:00 AM – 12:00 PM
Poster Board 29 | Abstract 2093
Presenter: Jennifer Jones, Sr. Product Marketing Specialist

Multiomic Co-Detection of Proteins, mRNA and Protein-Protein Interactions Reveal PD1-PDL1 Interactions in the Tumor Microenvironment of Bladder Cancer Patients Treated with anti-PD-L1
Monday, April 28 | 9:00 AM – 12:00 PM
Poster Board 3 | Abstract 2179
Presenter: Ge-Ah Kim, Sr. Scientist

Multiomic Fluorescent Co-Detection of Biomarkers in the Tumor Microenvironment Using a New RNAscope Assay on Roche DISCOVERY ULTRA
Monday, April 28 | 9:00 AM – 12:00 PM
Poster Board 28 | Abstract 2092
Presenter: Anushka Dikshit, Sr. Applications Manager

Identifying Immune Cell Phenotypes and Their Function by Using High Throughput Spatial Multiomics
Tuesday, April 29 | 2:00 PM – 5:00 PM
Poster Board 24 | Abstract 5318
Presenter: Anushka Dikshit, Sr. Applications Manager

Profiling the Tumor-Immune Landscape with a Same-Section Multiomics Assay
Tuesday, April 29 | 2:00 PM – 5:00 PM
Poster Board 10 | Abstract 5304
Presenter: Jacqueline Giliberti, PhD, Product Manager

Spatial Multiomics Reveals T-cell Activation and Exhaustion States in the Tumor Microenvironment
Wednesday, April 30 | 9:00 AM – 12:00 PM
Poster Board 12 | Abstract 6471
Presenter: Anushka Dikshit, Sr. Applications Manager

Poster Presentation In Collaboration
A Novel Protease-Free Workflow for Spatial Multiomics Analysis of the Tumor Microenvironment in Breast Cancer
Poster Board 21 | Abstract 170
Presenter: Dr. Tanni Rahman, HistoWiz

Dissecting the Immune Landscape in EBV+ Classical Hodgkin Lymphoma Following IL-23 Inhibition Using Single-Cell Hyperplex Immunofluorescence Analysis: A Case Report
Wednesday, April 30 | 9:00 AM – 12:00 PM
Poster Board 9 | Abstract 6468
Presenter: Dr. Janusz Franco-Barraza, Fox Chase Cancer Center

Translating clinically Validated Antibodies into a Multiplexed Immunofluorescent Panel for the Spatial Profiling of Lymphoid Malignancies
Monday, April 28 | 2:00 PM – 5:00 PM
Poster Board 4 | Abstract 2525
Presenter: Dr. Tania Pannellini, European Institute of Oncology (EIO)

For more information about Bio-Techne’s presence at AACR (Free AACR Whitepaper) 2025, visit View Source

On April 23, 2025 ImCheck Therapeutics reported an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2025, taking place from May 30 to June 3, in Chicago, Illinois, USA (Press release, ImCheck Therapeutics, APR 23, 2025, View Source [SID1234652062]). The presentation will focus on results from its ongoing open-label, randomized Phase I/II study EVICTION, including updated efficacy, safety and dose-selection data on the company’s lead γ9δ2 T-cell activator, ICT01, in combination with azacitidine and venetoclax for the treatment of older or unfit patients with newly diagnosed acute myeloid leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation at ASCO (Free ASCO Whitepaper) 2025 are:

Abstract Title: "γ9δ2 T-cell activation with ICT01 combined with azacitidine-venetoclax for older/unfit adults with newly diagnosed AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION"

Session: Oral Abstract Session S100a – Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant

Date: Monday, June 2, 2025

Time: 5:12 p.m.- 5:24 p.m. Central Time

The ASCO (Free ASCO Whitepaper) presentation will be available on ImCheck’s corporate website after the presentation has been held.

On April 23, 2025 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will be delivering a rapid oral presentation of randomized Phase I trial data of individualized neoantigen therapeutic cancer vaccine TG4050 in head and neck cancer at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (Press release, Transgene, APR 23, 2025, View Source [SID1234652061]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A rapid oral presentation is part of a formal session, with a six-minute oral presentation format. It aims at sharing clinical data that stood out among many submissions.

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup.

The 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), annual meeting will take place in Chicago from May 30 to June 3, 2025.

TG4050— Rapid oral presentation details:

Title: "Randomized Phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced head and neck squamous cell carcinoma (HNSCC) patients."

· Session title: Rapid Oral Abstract Session

· Date and Time: Sunday, June 1, 12:06 p.m. CDT

· First Author: Prof. C. Le Tourneau

· Abstract Number: 6016

TG4050 is an individualized neoantigen therapeutic cancer vaccine being developed for solid tumors which is based on Transgene’s myvac technology and powered by NEC’s longstanding artificial intelligence and machine learning expertise. TG4050 is being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Transgene intends to present 24-month follow-up data from patients enrolled in the Phase I part of the trial. Patients are currently being enrolled in the Phase II part of this trial.

TG4001— Poster presentation details:

Title: "Randomized Phase II trial evaluating the combination of TG4001, an HPV16 therapeutic cancer vaccine and avelumab in patients with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer."

· Session title: Developmental Therapeutics ̶ Immunotherapy

· Date and Time: Monday, June 2, 1:30 p.m. CDT

· First author: Prof. C. Le Tourneau

· Abstract number: 2638

The abstracts will be available on the ASCO (Free ASCO Whitepaper) website on May 22, 2025, at 5 p.m. ET.

On April 23, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported its results for the first quarter ending March 2025 (Press release, Alligator Bioscience, APR 23, 2025, View Source [SID1234652060]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

" With the continued strengthening of mitazalimab’s clinical profile—including 24-month survival data, further dose validation, and positive regulatory alignment—we are well-positioned for Phase 3 initiation in the second half of 2025. Combined with enhanced financial flexibility following the rights issue and strategic portfolio optimization, we are advancing with confidence toward our goal of delivering transformative immunotherapies for patients with hard-to-treat cancers."
Søren Bregenholt, CEO of Alligator Bioscience
BUSINESS UPDATE
Mitazalimab

Announcement of encouraging overall survival benefit from the Phase 2 trial OPTIMIZE-1, with 24-month follow-up data showing a 29.4% survival rate for mitazalimab in combination with mFOLFIRINOX—three times higher than estimates for chemotherapy alone.
Top-line data from the 450 µg/kg back-filled cohort in OPTIMIZE-1 further support 900 µg/kg as the recommended Phase 3 dose.
Additional positive survival data for mitazalimab demonstrated through a literature-based indirect comparison, showing an incremental overall survival benefit and further supporting progression to Phase 3.
Successful completion of End-of-Phase 2 meeting with the FDA with positive feedback and alignment on clinical development strategy and Phase 3 trial design.
Company

Approval of rights issue and reverse share split at Extraordinary General Meetings held on 13 January and 27 March 2025, respectively.
Successful completion of rights issue in February 2025 with gross proceeds of SEK 153 million; BTUs converted and units issued to guarantors and Fenja Capital.
Peer-reviewed publication of data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer confirming its immunomodulatory effects.
FDA grants Chinese Shanghai Henlius Orphan Drug Designation in gastric cancer for Alligator’s out-licensed candidate HLX22.
Publication of Alligator’s Annual Report for 2024 on 27 March 2025, outlining operational and financial highlights.
FINANCIAL SUMMARY FOR Q1 2025
The financial summaries for the quarterly periods ending 31 March 2025 and 31 March 2024 are presented below.

All amounts in MSEK,
unless specified January – March
2025 January – March
2024
Net sales - 7.0
Operating profit/loss -43.7 -59.6
Profit/loss for the period -8.3 -62.8
Cash flow for the period -34.6 -26.2
Cash and cash equivalents 28.9 40.0
Earnings per share before and after dilution, SEK -1.1 -95.4
The full report is attached as a PDF, and is also available on the company’s website: View Source

Alligator will host a webinar on Thursday, April 24 2025, at 2 p.m. CEST/ 8 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the January – March 2025 interim report, which will be followed by a Q&A session.

On April 23, 2025 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to take place May 30- June 3, 2025 in Chicago, Illinois (Press release, Sellas Life Sciences, APR 23, 2025, View Source [SID1234652059]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentation details:

Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines.

Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 PM CDT

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Location: Hall A – Posters and Exhibits

Abstract #: 3121

Poster Board #: 436

The full text of the abstract will be released by ASCO (Free ASCO Whitepaper) on May 22, 2025, at 5:00 PM EDT on asco.org/abstracts.

SLS009 is currently being investigated in a Phase 2 open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine including AML patients with ASXL1 mutations. Initial clinical safety and efficacy data are available. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more information on the study, visit clinicaltrial.gov identifier NCT04588922.